Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

and Esperion had been looking at the CLEAR results to accelerate take-up. Arguably just as important was the expected cash injection from Daiichi Sankyo, given that Esperion ended 2022 with around ...

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with ...

Daiichi Sankyo reported full-year revenue of JPY 1,886 billion and core operating profit of JPY 332 billion. It issued full-year guidance of JPY 2 trillion revenue and JPY 350 billion core ...

In January 2025, Daiichi Sankyo reported FY2024 Q3 revenue of ¥1,367.6 billion [~$9.16 billion], up 16.6% YoY, with core operating profit rising to ¥229.0 billion [~$1.53 billion] (+33.0%).

(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN), Plus ...